Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Bullboard (TSX:GUD)

View:
Post by gudisgoodon May 11, 2023 7:38am

2023 Guidance Updated: +$20M

Also lower range of EBITDA from 13% to 14%.
Post by MrMugsyon May 11, 2023 7:04am

This should be your first clue ...

Jonathan Ross Goodman Elected 57,085,576 95.03% 2,985,127 4.97% James C. Gale Elected 59,496,395 99.04% 574,308  ...more  
Comment by GoldenInvestoron May 10, 2023 12:57pm

RE:Last Years Numbers to beat.

re this shareholder at first glance it seems to be a different family office in quebec.  I think G2S2 is also based out east. It appears to be a suburb of montreal. smart investors. big ...more  
Comment by EbbFlow88on May 10, 2023 12:49pm

RE:Last Years Numbers to beat.

Interesting find about Medici. They are not new but seem to have increased their holding. They've been shareholders for years. There's also another fund manager Tim McElvaine who owns knight ...more  
Post by wofatson May 10, 2023 11:59am

Last Years Numbers to beat.

These are the results for 1st quarter last year . These are the numbers that they should beat . They have 150 million still in the bank and they will need to raise capital ...more  
Comment by EbbFlow88on May 10, 2023 8:37am

RE:Share count ...

Around 2017-18 it was at around 143M shares. I think that was the peak
Post by MrMugsyon May 10, 2023 8:29am

Share count ...

Can anyone recall the peak of GUD's share count? Was it around 130 MM shares ?
Comment by MrMugsyon May 10, 2023 8:11am

RE:April Buybacks: Roughly 900K Shares

And a few more on top of that. Below 100M shares fairly quickly - IMO. Filed 2023-05-09 12:46   Tx date 2023-04-30 $GUD Knight Therapeutics ...more  
Comment by wofatson May 09, 2023 5:30pm

RE:A few things to note, upcoming!

Maybe the shorts will get squeezed a little this time. 3% of the stock is short. There is also a new item on Sedar for those who care it's in French. The interest in the stock should start picking ...more  
Post by GoldenInvestoron May 09, 2023 3:54pm

National post article

Showing how Opiod crisis actuall getting larger. from today May 9!  - 'Safer Supply' FUELLING OPIOID CRISIS
Post by GoldenInvestoron May 09, 2023 1:12pm

& continued share buybacks

Pretty interesting... -less shares, continuing profits... -increased tailwinds 
Post by GoldenInvestoron May 09, 2023 1:10pm

A few things to note, upcoming!

1) the earnings release on Thursday 2) samira in NYC next Tuesday
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities